Latest code release is live with fixes to most major bugs resulting from our 15-month rewrite of the underlying code base, including: Ignores, Ignore Replies, View Thread, Hide Replies, Inbox Folder Access, & other random issues. Please report any remaining bugs you are aware of & we'll get cranking on the next round of fixes. Send PM to Admin, email to admin@investorvillage.com. Thanks!
okay, you "fully expect" a lot of positives for dcth in the near term... i've been here for 2-3 years and most here have always been very positive for all things dcth... huge potential/totally undervalued... today's pps is a great buying op... yada, yada, yada.
but last week, the market was valuing dcth at 2.50/sh... it was pricing lotsa risk in its valuation for this "$1B potential" drug.
now this week, dcth prices a measly $20M secondary at $1.50/sh... that smacks of desperation.
biotech's raise capital when they can... not when they need it.
could this capital raise be a tell that dcth is very concerned that the fda is gonna require a new trial(s) with the gen2 filter to refile the nda ?
nah, if that was the case, Hobbs shoulda/woulda stated that possibility, right ?... then again, maybe he did when they announced this secondary.
